share_log

InterCure (OTCMKTS:IRCLF) Trading Down 2.1%

InterCure (OTCMKTS:IRCLF) Trading Down 2.1%

InterCure(OTCMKTS:IRCLF)股價下跌2.1%
Defense World ·  2022/09/13 02:21

InterCure Ltd. (OTCMKTS:IRCLF – Get Rating) shares fell 2.1% on Monday . The company traded as low as $6.15 and last traded at $6.18. 9,400 shares were traded during mid-day trading, an increase of 3% from the average session volume of 9,097 shares. The stock had previously closed at $6.31.

InterCure Ltd.(OTCMKTS:IRCLF-GET Rating)股價週一下跌2.1%。該公司股價低至6.15美元,最新報6.18美元。午盤成交量為9,400股,較9,097股的平均日成交量增加3%。該股此前收盤價為6.31美元。

InterCure Trading Down 2.1 %

InterCure降價2.1%

The business's 50 day moving average price is $6.18.

該業務的50日移動均線價格為6.18美元。

About InterCure

關於InterCure

(Get Rating)

(獲取評級)

InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

InterCure有限公司及其子公司在以色列和國際上從事醫用大麻產品的研究、種植、生產、營銷和分銷。它還投資於BioMed部門。該公司成立於1994年,總部設在以色列赫茲利亞。

Read More

閲讀更多內容

  • Get a free copy of the StockNews.com research report on InterCure (IRCLF)
  • Darden Restaurants Takes the Low Road Against Inflation
  • Why These 3 Stocks Are Off to Hot September Starts
  • Inflation Doesn't Differentiate, But it's Impact Does
  • 3 Downgraded Must-Have Stocks To Put On Your Watchlist
  • This Is What To Expect From The Q3 Earnings Reporting Season
  • 免費獲取StockNews.com關於InterCure的研究報告(IRCLF)
  • 達頓餐廳走低通脹之路
  • 這3只股票為何在9月火爆開盤
  • 通貨膨脹沒有差別,但它的影響有差別
  • 3只被降級的必備股票放在你的觀察名單上
  • 這是對第三季度收益報告季節的預期

Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.

接受InterCure Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對InterCure和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論